Q3 EPS Estimate for Precision BioSciences Boosted by Analyst

Key Points

• HC Wainwright analysts have raised their Q3 2025 earnings per share estimate for Precision BioSciences to ($0.31), up from a previous estimate of ($0.38), while maintaining a "Buy" rating with a target price of $60.00.
• Precision BioSciences reported a significantly higher loss of ($2.13) EPS for the latest quarter, which was far below the analysts' consensus estimate of ($0.09).
• Insider trading activity indicates that CFO John Alexander Kelly sold nearly 15,000 shares, decreasing his ownership by 16.79%, amid a backdrop of varied institutional investment strategies in the company's stock.

Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Equities research analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for Precision BioSciences in a research note issued to investors on Monday, August 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.31) per share for the quarter, up from their prior estimate of ($0.38). HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences' current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences' FY2025 earnings at ($4.57) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at $0.94 EPS, FY2026 earnings at $0.47 EPS, FY2027 earnings at $0.93 EPS, FY2028 earnings at $1.15 EPS and FY2029 earnings at $0.15 EPS.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($2.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($2.04). Precision BioSciences had a negative net margin of 6,205.79% and a negative return on equity of 176.47%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $6.27 million.

Precision BioSciences Trading Up 7.1%

NASDAQ:DTIL opened at $4.69 on Thursday. The firm has a market cap of $55.30 million, a PE ratio of -0.53 and a beta of 1.52. The stock has a fifty day moving average price of $4.70 and a 200 day moving average price of $4.92. Precision BioSciences has a 12-month low of $3.61 and a 12-month high of $11.09. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.66.

Insider Transactions at Precision BioSciences

In other news, CFO John Alexander Kelly sold 14,827 shares of Precision BioSciences stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.26, for a total transaction of $63,163.02. Following the sale, the chief financial officer owned 73,485 shares in the company, valued at approximately $313,046.10. The trade was a 16.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Precision BioSciences

Institutional investors have recently added to or reduced their stakes in the business. Miller Financial Services LLC purchased a new stake in shares of Precision BioSciences during the 1st quarter worth approximately $48,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Precision BioSciences by 22.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company's stock valued at $59,000 after acquiring an additional 2,805 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Precision BioSciences during the 4th quarter worth $67,000. Jane Street Group LLC acquired a new stake in shares of Precision BioSciences during the 4th quarter worth $146,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Precision BioSciences during the 4th quarter worth $179,000. Hedge funds and other institutional investors own 37.99% of the company's stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.